Curevo Announces Positive Updated Phase 2 Data for Amezosvatein Shingles Vaccine Updated Phase 2 data one year after the second vaccine dose, the anti-gE antibody immune response to amezosvatein continues to be non-inferior to Shingrix

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 and expect to initiate a pivotal trial in the 2nd line by early...

Curevo Vaccine to present at the 43rd Annual J.P. Morgan Healthcare Conference Curevo Vaccine will present at the 2025 JPM Healthcare Conference on Wednesday January 15th.

Kailera Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference Ron Renaud, Kailera's President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025.

Artios Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference CAMBRIDGE, United Kingdom and NEW YORK, December 19, 2024 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, today...